Open Label Trial of Rapastinel (Formerly GLYX-13) in Individuals With Obsessive-Compulsive Disorder

Exclusion Criteria

• •Psychiatric conditions that make participation unsafe (schizophrenia \[either self or first degree relative e.g. siblings, parents\], history of violence, severe depression, eating disorder, substance abuse in prior year\[including nicotine\], lifetime substance dependence disorder \[except nicotine\])
• •Female patients who are either pregnant or nursing
• •Enrolled in or planning to enroll in Cognitive Behavioral Therapy.
• •Medical conditions that make participation unsafe (e.g., high blood pressure, head injury)
• •Currently on medications that make participation unsafe
• •History of allergy, sensitivity, or intolerance to N-methyl-D-aspartate receptor (NMDAR) ligands including ketamine, dextromethorphan, memantine, methadone, dextropropoxyphene, or ketobemidone.
• •Psychiatric conditions that make participation unsafe (schizophrenia \[either self or first degree relative e.g. siblings, parents\], history of violence, severe depression, eating disorder, substance abuse in prior year\[including nicotine\], lifetime substance dependence disorder \[except nicotine\])
• •Female patients who are either pregnant or nursing
• •Enrolled in or planning to enroll in Cognitive-Behavioral Therapy.
• •Patient judged unlikely to be able to tolerated a medication washout.
• •Medical conditions that make participation unsafe (e.g., high blood pressure, head injury)
• •Currently on medications that make participation unsafe
• •History of allergy, sensitivity, or intolerance to N-methyl-D-aspartate receptor (NMDAR) ligands including ketamine, dextromethorphan, memantine, methadone, dextropropoxyphene, or ketobemidone.